Audrey’s Life Science Meeting Picks for Jan. 22, 2017 – April 2017
Complimentary Service of AudreysNetwork.com
Jan. 22, 2017
*******************************************************************
PMWC 2017 Silicon Valley, Jan. 23-25, 2017

Date and Time: Monday – Wednesday, Jan. 22-25, 2017, 8:00am - 5:00pm
Location: Computer History Museum, 1401 N Shoreline Blvd., Mountain View, Ca 94043
Get details and registration information at http://www.pmwcintl.com/2017sv/

Contact: Tal Behar
Contact Phone: 650-740-2776
Contact Email: talb@pmwcintl.com

Event Description
The Precision Medicine World Conference (PMWC), formerly known as the Personalized Medicine World Conference will hold its 11th Conference on January 22-25 featuring recent advances and challenges in the field.
Some confirmed speakers:
James Allison, MD Anderson
Brad Gray, Nanostring
Larry Corey, Juno
Fred Pla, Genomic Health
Harold Paz, Aetna
Jay Flatley, Illumina
Ron DePinho, MD Anderson
Lee Hood, Providence
We expect 1500 attendees.
*******************************************************************
UCSC Extension Course, Mondays, Jan. 23-April 10, 2017

Event: Validating Software for Medical Devices and Emerging Technologies
Date and Time: Monday, Jan. 23, 2017
Location: UCSC Ext 3175 Bowers Ave, Santa Clara
Event: “Validating Software for Medical Devices and Emerging Technologies”
Dates: January 23—April 10

Course Description
This course covers the software validation requirements of Class II and III medical device software, mobile medical apps, medical device data systems, manufacturing software, automated test software, process software, quality system software and spreadsheets.
*******************************************************************
Bio2Device Group, Tuesday Morning, Jan. 24, 2017

Topic: “Q4 numbers, views from JP Morgan and an open discussion of what the Trump Administration’s Impact may be on Healthcare”
Date and Time: Tuesday, Jan. 24, 2017, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
Speaker/Moderator: Harry Wachob and Attendees
There is no fee nor registration required for morning meetings.
Topic Description
NO invited speaker. A brief discussion of the preliminary 16Q4 VC numbers, a review of opinions and thoughts about the JP Morgan Life Science Conference, and an open discussion of what the Trump Administration's impact will be on Healthcare and the life sciences in Silicon Valley.

Speaker Bio
Harry Wachob is the Founder and President of the Bio2Device Group. He is an experienced engineering leader in materials science, biomedical device engineering and R&D. He has directed and mentored multidisciplinary teams in solving complex technical issues in order to improve the safety, reliability, and performance of medical devices. Most recently, he was the Managing Materials Scientist at Xoft. Previously he was Director of Engineering for Aerogen, a biopharmaceutical company specializing in novel aerosol drug delivery. Prior to that, Harry was Managing Engineer at Exponent/Failure Analysis Associates where he guided research and development, and product failure investigations covering a broad range of medical and industrial applications. He received his engineering degrees in Materials Science & Engineering from Cornell University

**************************************************************************
JLABS, Thursday Morning, Jan. 26, 2017

Speaker: Jonathan Norris | Managing Director, Silicon Valley Bank
Date and Time: Thursday, January 26th, 8:00-10:00 AM, presentation begins at 8:30 sharp
Location: JLABS @ SSF, 329 Oyster Point Blvd – 3rd Floor, South San Francisco, CA
Pricing: $12 | General Public ($8.40 with discount)
        $8 | Student/Academic ($5.60 with discount)
        $25 | Onsite


In cooperation with JLABS (http://jlabs.jnjinnovation.com/locations/jlabs-ssf)

Topic Description
2016 has been another wild ride, with early surprises and a bumpy start. With 2016 in the review mirror, Jon Norris takes a look at - and makes sense of - the past trends to provide an informed look into 2017.

As the 2017 investment market takes shape, what can we expect for the IPO and M&A markets? Jon will share his expertise and provide insight into:
  · How the 2016 healthcare landscape compares to previous years
  · Current and total healthcare and sector investments
  · Which Biopharma indications attracted the most funds
  · Which venture firms are most active
  · Changes in the past crossover phenomenon
  · Exits: the trends in IPOs and M&A's
At the end of this talk you should be informed as to who is investing, and the type of deals and exits that are likely to be executed in 2017.

Contact: http://www.biopharmaconsortium.com/contact/

Speaker Bio:
Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations.
In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms.
Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
About Jon
Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.

California Life Sciences Association, Thursday Afternoon, Jan. 26, 2017

Topic: "Federal Grants Management - Accounting and Compliance"
Date and Time: Thursday, January 26, 2017 from 11:00 AM to 2:00 PM (PST)
Registration & Networking Lunch: 11:00 am – 12:00 pm
Presentation: 12:00 — 1:00pm
Networking: 1:00 — 2:00pm
Location: CLSA Event Center, 250 East Grand Ave., Suite 26, South San Francisco, CA 94080
Fees: Free to CLSA members and $75 to nonmembers

Event Description
Do you rely on government grants to fund your operations? Stay ahead of the curve and learn the best practices of regulatory compliance at our January 26th event! From conducting clinical trials to bringing products to market to expanding operations, many life sciences companies turn to government grants. Grants, however, come with a complex regulatory environment that must be complied with—especially in the new age of Uniform Grant Guidance. This lunch and learn will highlight important changes and share best practices with your company’s management, finance/accounting professionals, and grant managers so they stay on top of federal grants management accounting and compliance requirements.

Speaker Bio
Kinman Tong, Audit Senior Manager, Moss Adams LLP

Kinman has over 13 years of experience in accounting, auditing, and consulting for not-for-profit, health care, and life sciences organizations. He manages audits of numerous engagements for organizations receiving federal awards under Title 2 CFR Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance), such as health care providers, foundations, life science technology companies, and alternative energy companies. He is also the regional champion for the Greater Bay Area for federal compliance audits and is a member of Moss Adams’ Single Audit Technical Reviewer, a committee dedicated to the federal compliance audits. He has extensive experience working with organizations with HHS NIH, DOD, and DOE SBIR/STTR grants.

Representative clients served include 23andMe, Advanced Cell Diagnostics, Bell Biosystems, Chrono Therapeutics, Elysium Therapeutics, HeartVista, Intrinsic LifeSciences, Mission Bio, Mynosys Cellular Devices, Neurogenetic Pharmaceuticals, PaxVax Global, and Trellis Bioscience.

PBSS, Friday MidDay, Jan. 27, 2017

Topic: “Stem cell gene therapy to cure diseases: overview, a success story and current advances”
Speaker: Maria Grazia Roncarolo, MD
Date and Time: Friday, Jan. 27, 2017, 11:00-13:30
Registration fee (USD):
Location: Crowne Plaza Hotel, Foster City
Registration: See details at https://www.pbss.org/aspx/login01.aspx
Registration deadline: 1/18/2017 (it will close sooner if the seating cap is reached)

Topic Description

Millions of people worldwide have serious genetic and acquired diseases for which there is no cure. Yet exciting advances in stem cell and gene therapy are creating opportunities to not only treat, but actually cure these diseases. The rate of scientific discovery has accelerated at such a pace that outcomes considered science fiction just ten years ago are now being seriously considered and pursued by experts around the globe. Genetic diseases of the blood, the immune system and the nervous system are now cured by inserting a normal copy of the relevant gene into somatic cells.

Primary immunodeficiencies (the bubble boys), were originally considered good candidates for gene therapy because they were well understood at the molecular level and because the target cells, the blood stem cells, are easily accessible and can be explanted, genetically corrected in the laboratory, and then retransplanted. Gene therapy with blood stem cells has been successfully developed as therapeutic strategy for several forms of primary immunodeficiency, including severe combined immunodeficiency (SCID)-X1, adenosine deaminase (ADA)-deficient SCID, and chronic granulomatous disease (CGD). Initial approaches were based on ex vivo retroviral vector mediated gene transfer of the therapeutic gene into the patient’s blood stem cells. The inclusion of reduced-dose conditioning in the ADA-SCID has allowed the engraftment of multipotent gene-corrected HSC at substantial level. Results of the ADA-SCID gene therapy trials have demonstrated safety, long-term restoration of immune competence and clinical benefit. Based on the data in the first 18 patients the product has been licensed to GSK that recently received European marketing authorization for Strimvelis.

The use of self-inactivating lentiviral vectors is providing significant advantages in gene regulation and reduction in the potential for adverse mutagenic events. Lentiviral vectors are currently used in clinical trials to cure SCID, Wiskott Aldrich syndrome and other
primary immunodeficiencies but also blood disorders, such as thalassemia and sickle cell anemia, and metabolic diseases.

The prospects for continuing advancement of gene therapy to wider applications remain strong. Emerging methods for direct gene replacement by genome editing will broaden the use of gene therapy to other genetic and acquired diseases. In summary, in the near future the continuing advancement of stem cell and gene therapy will make it possible “to cure what is curable and make curable what is not”.

Speaker Bios

Maria Grazia Roncarolo, MD
George D. Smith Professor of Pediatrics and Medicine
Division Chief, Pediatric Stem Cell Transplantation and Regenerative Medicine
Co-Director, Bass Center for Childhood Cancer and Blood Diseases
Co-Director, Institute for Stem Cell Biology and Regenerative Medicine
Department of Pediatrics, Stanford School of Medicine

Dr. Roncarolo has made outstanding contributions to translational research in the fields of immunology and gene therapy. Her translational research studies have led to greater understanding of the mechanisms underlying immune tolerance and have been of paramount importance to the development of novel therapies for patients with genetic and acquired diseases of the hematopoietic and immune systems.

She contributed to the elucidation of the mechanisms underlying the induction and breaking of tolerance in stem cell transplantation/organ grafts/autoimmune diseases and gene therapy. Specifically, she discovered a new subset of human T regulatory cells with immune regulatory and suppressor functions, named Type 1 (Tr1) cells. She established that these cells were present in tolerant patients following hematopoietic stem cell transplantation. Subsequently, she isolated these cells from both mice and man, demonstrating that they are responsible for induction and maintenance of tolerance to allo- and self-antigens and food- and environmental- antigens. Recently, she discovered that the surface molecules CD49b and LAG3 are specific biomarkers for this subset of T regulatory cells, which allows for their isolation for therapeutic purposes and in vivo tracking in patients. She was the principal investigator of the first clinical trial using these ex-vivo generated donor-derived Tr1 cells to prevent the occurrence of severe graft-versus-host disease in leukemia patients undergoing haploidentical hematopoietic stem cell transplantation.

Dr. Roncarolo also discovered that Rapamycin favors expansion of another subset of human T regulatory cells, CD25+FOXP3+ Treg cells, allowing for their therapeutic use. She further demonstrated that treatment with Rapamycin and IL-10 induces tolerance in vivo by promoting differentiation of Tr1 cells and expansion of CD25+FOXP3+ T regulatory cells. She showed that specific Ag-targeting to the hepatocytes results in immunological tolerance mediated by CD25+FOXP3+ T regulatory cells.

Parallel to her studies on immunological tolerance, Dr. Roncarolo has investigated the pathological mechanisms responsible for genetic diseases of the hematopoietic and immune system in order to design therapies that will ultimately cure afflicted patients.

Dr. Roncarolo was the principal investigator for the first lentiviral-vector based gene therapy trial for patients with Wiskott-Aldrich syndrome, which demonstrated safety and efficacy of this therapy. In addition, she was the principal investigator for the first successful gene therapy trial for Severe Combined Immunodeficiency (SCID) patients lacking adenosine deaminase (ADA), a purine metabolism disorder that results in severe immunodeficiency and death. In this trial she introduced a new therapeutic conditioning regimen for the host, which favored the outgrowth of the gene corrected cells, resulting in the most successful clinical outcome for this formerly non-treatable genetic disease. Based on these results, gene therapy for ADA-SCID has obtained Orphan drug status from both the FDA and EMEA and recently has received European Commission approval to market under the name of
Strimvelis. This is the first stem cell gene therapy product, which received market authorization.

*******************************************************************

QB3, Tuesday, Jan. 31, 2017

Event: Join the QB3/Rosenman Institute tour of Applied Materials' state-of-the-art materials fab in Sunnyvale
Date and time: Tuesday, Jan. 31, 2017, 10 am to 3 pm
Agenda
- Tour of Maydan Technology Center
- Lunch
- Business unit pitches by Applied Materials
- QB3/Rosenman company pitches
Location: Maydan Technology Center, 974 E. Arques Ave, Sunnyvale

Event Description
Applied Materials is the world's largest maker of semiconductor equipment. Applied, a partner of QB3 and the Rosenman Institute, our medical devices initiative, is also a materials engineering leader with the ability to manipulate matter with atomic precision at scale. Applied has a range of capabilities and process expertise in areas including high speed imaging, flexible electronics for wearables and implantables, thin films, and 3D deposition of biological materials.

Would you like to tour their facility? Applied has offered us a January 31 tour of their Maydan Technology Center in Sunnyvale. The group is limited to 15.

Some of Applied's Capabilities
- Imaging: high-speed; wide field of view (coverage)
- Roll-to-roll: thin flexible electronics to create sensors or circuits for wearables or implantables
- Chemistry: thin film and 3D deposition of biological materials
- Metrology/data: 50GB of data pass through Applied's machines per second and they have an internal cloud computing capability as well as a data science group; high speed image analysis, high-speed data acquisition

*******************************************************************

Bio2Device Group, Tuesday Morning, Jan. 31, 2017

Topic: GutCheck: an "EKG for the Gut"
Speaker: Steve Axelrod, CEO, G-Tech Medical
Date and Time: Tuesday, Jan. 31, 2017, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
There are no fees or registration required for morning meetings.

Topic Description
Gastrointestinal (GI) disorders affect 15 - 20% of the population, and GI dysfunctions such as post-operative ileus are common in millions of surgeries per year in the US. Common diagnostic tests such as colonoscopies, CT scans and other imaging modalities reliably detect important anatomic problems (tumors, inflammation), but are not effective at identifying problems that are inherently functional. Functional GI issues, e.g Irritable Bowel Syndrome and the return of function after surgery, are not well addressed by anatomic tools. In functional issues, everything looks fine, but it doesn’t work fine. G-Tech Medical is
an early stage startup medical device company headquartered at the Fogarty Institute in Mountain View. We're developing an "EKG for the gut" in the form of a wireless wearable patch which reads electrical signals from the stomach, small intestine and colon and determines their activity under realistic physiological conditions. This talk will discuss the medical need, technology and science, and the current status of the development.

Speaker Bio
Steve holds a BS in Physics from UConn and a PhD in Elementary Particle Physics from Yale. He played with technologies like particle detection and fast pulse instrumentation, sub-kelvin cryogenics, superconducting magnets, NMR and ESR, high vacuum systems and data acquisition and analysis. He remembers using Bitnet and Arpanet before there was a WWW, and sending emails to friends working at distant particle accelerators using PDP-10 and VAX terminals.

After graduation he took a postdoc position at Stanford and when that ended refused to leave the Bay Area. The next 15 years were spent at Measurex (later Honeywell) developing on-line measurement systems such as nuclear and X-ray basis weight and thickness sensors, infrared moisture sensors and large electromechanical scanning systems. In 2003 he joined Xoft Inc, a startup developing a 2mm diameter 50kV X-ray source for radiation therapy applications, and has been in the medical device field ever since. He has been CEO of G-Tech Medical since joining the company in late 2011. Steve has been an individual contributor and has held various levels of management roles from R&D Manager to CEO, but has never been able to fully break away from the science and technology.

Palo Alto AWIS, Tuesday Evening, Jan. 31, 2017

Topic: “Learn to Lead: Conduct Your Orchestra”
Date and Time: Tuesday, January 31, 2017, 7- 9 PM
7:00-7:30: Networking dinner
7:30-7:45: Announcements
7:45-9:00: Workshop
Location: PARC Auditorium, Xerox, 3333 Coyote Hill Rd, Palo Alto, CA 94304, USA
Fees and registration: Go to website to get details and register at http://pa-awis.weebly.com/
Cost and url to register not posted as yet.

Topic Description
Every team brings its own leadership challenges. Learn from Conductor Nathaniel Berman, Faculty Member at University of California Santa Cruz (UCSC), how an orchestra ensures that everybody listens and contributes as a team to create a harmonious experience. Join us for an interactive session to explore the interplay of listening and reacting, and to understand how non-verbal cues can serve as a powerful leadership tool.

Speaker Bio
Nathaniel Berman maintains an active presence as a performer and music educator in the San Francisco Bay Area. Equally dedicated to new music and interdisciplinary collaboration, Mr. Berman is a Faculty Member of the music department at UCSC; Conductor of the Wind Ensemble and Concert Choir; Music Director of the Santa Cruz County Youth Symphony; Artistic Director and Conductor of the San Francisco-based new-music ensemble Wild Rumpus. Mr. Berman received his Master’s degree in conducting from UCSC, where he studied with Nicole Paiement. His first instrument was trumpet, and he grew up playing duets with his dad, a jazz pianist and singer.
*************

WIB, Thursday Morning, Feb. 9, 2017

Event: "WIB-National Webinar 'Class II Medical Device Innovation and IP Strategy: Case Study in Women’s Health Products,"
Speaker: Debra Kurtz, President, Kurtz Consulting Inc
Date and Time: February 9, 2017, 1:00 p.m. – 2:00 p.m. EST*(10:00 – 11:00 am PT)  
* - Please note this webinar's time is listed in Eastern Standard Time. Register at http://www.womeninbio.org/

Webinar Description

Combining motherhood and a career is a juggling act, and was even more so before the breast pump. Women didn't always have access to pumps in the workplace, however nowadays many breastfeeding mothers rely on a breast pump when returning to work to help extend breastfeeding and the work/life balance. Join us as Debra Kurtz, President, Kurtz Consulting Inc, discusses:
the history of breast pump innovation
how these class II medical devices assist with maternal employment
leverage user insights to drive product requirements and IP strategy
the opportunities we have to improve health products, advance employee benefits, and improve work/life balance for future generations of women

Registration Deadline
February 8, 2017

Venue
Please be sure you have complete the second portion of your registration with Go To Webinar. This second registration must be completed to receive your event specific link, which will allow you access to the webinar.

*************

Bio2Device Group, Tuesday Evening, Feb. 14, 2017

Topic: "Immuno-oncology 2017 - The crux of the matter, the thrill of the chase"
Speaker: Alex Franzusoff, PhD, Senior Vice President, Research and Product Development, PACT Pharma, Inc
Date and Time: Tuesday, Feb. 14, 2017, 6:00 pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto
Cost:  
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at Bio2DeviceGroup.org website.

Topic Description
The clinical data and product approvals for immune checkpoint inhibitor (ICI) monoclonal antibody drugs, particularly those targeting PD-1, PD-L1 and CTLA-4, promise a revolution in cancer therapeutics known as immuno-oncology (I-O). In the approved indications of metastatic melanoma, lung and bladder cancers, patients have experienced rapid and
durable clinical responses upon treatment with these ICI drugs. Patients, clinicians, regulators, scientists, investors and the public look upon these developments with high anticipation – namely the ability to recruit one’s own immune system to cure cancer or to convert it into a manageable chronic disease. Yet, the evidence that 70% of patients in those cancers, and even more in other solid tumor indications, do not respond similarly or soon recur have inspired intensive investigations into the crux of the matter. The central premise of the I-O paradigm involves ‘stepping on the gas’ and ‘releasing the brakes’ of T cell immunity, as an automobile metaphor to propel patients into significant clinical benefit. Preclinical and clinical studies of combination therapies, biomarkers, bioengineering and diagnostics are providing key insights, with much more progress needed.

In this presentation, we will consider evidence from several platform technology approaches with promising potential to push meaningfully on the ‘gas’, thus illuminating the thrill of the chase and how we may still significantly contribute to and benefit from expanding the immuno-oncology paradigm.

******************************************************************************

**HBA, Webinar, Wednesday Evening, Feb. 15, 2017**

Event: “Webinar: Career Advice For Scientists and Other Smart Women”
Featured speakers
Linda Brock
Scientist, virology and immunology
Laura Rush
Executive director, clinical and translational research unit
Ohio University
Jennifer Cook
Head of pharma, Europe region; 2016 HBA Woman of the Year
Roche
Michele Holcomb
COO and senior vice president, portfolio, search and partnerships - global research and development
Teva Pharmaceuticals
Suzanne Schwartz
CDRH associate director for science and strategic partnerships
FDA
Date and Time: Wednesday, February 15, 2017, 6:30PM - 7:30PM EST, 3:30 – 4:30 PM PT
Please note: This webinar will take place from 6:30 – 7:45 PM ET. Please convert into your local time zone and mark your calendar accordingly.
Agenda
6:30 - 6:35 PM    Introduction and overview of Women in Science affinity group
6:35 - 7:20 PM    Presentation and panel discussion
7:20 - 7:45 PM    Q&A and closing
Pricing
Registration NamePrice LevelRegularIndividual registrationMember$25.00Individual registrationNon-Member$35.00Site license registrationMember$350.00Site license registrationNon-Member$350.00
Register at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=B65806B0-02C6-E611-A5C2-0050569C00A7

Event contact
Juliana Wood
Competencies
5. Determined to achieve
9. Networks and ethically self-promotes

Webinar description:
The scientific career is tough. The skills and ability to create knowledge about biology and science is uniquely difficult. In order to create a successful work product, typical characteristics include perfectionism and individuals who are not quitters. Typically, most of the experiments a scientist does do not work, thus these inherent traits are needed to succeed. However, these skills may not be beneficial when navigating a scientific career.

This webinar will also be viewed in different live Women in Science events throughout the HBA. We will be connecting the live events and webinar through the use of Twitter. Follow #HBIAImpact and #HBAWIS to join the conversation.

Registration information
Event is open to: HBA members and nonmembers
Online registration available until one hour before the live broadcast begins.

*The single site license is for use when a group of individuals view the live webinar broadcast together in a classroom or group setting at one (1) physical location. The webinar may not be rebroadcast, retransmitted or recorded.

This webinar is nonrefundable.

Learning objectives
1. Recognize how four prominent scientists have navigated their careers in very different sectors including industry, academia and government
2. Identify how your technical training may enhance your own professional advancement or challenge it

******************************************************************************

HBA Supper Club, Thursday Evening, Feb. 23, 2017

Date and Time: Thursday, Feb. 23, 2017, 6:00 – 8:30, 2017
Agenda
6:00 - 6:30 PM Drinks and networking
6:30 - 8:30 PM Dinner
Location: Salito's, 1200 Bridgeway, Sausalito, CA 94965
650-343-1226
Registration information
Event is open to: HBA members and nonmembers
Onsite (walk-in) registration: Is NOT allowed

Member rate:
$10 until November 9, 2016
$15 after November 9, 2016
Nonmember rate:
$15 until November 9, 2016
$20 after November 9, 2016

Registration information
The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership. The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

<table>
<thead>
<tr>
<th>Registration Name</th>
<th>Price Level</th>
<th>Member</th>
<th>Non-Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular registration</td>
<td>Member</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Regular registration</td>
<td>Non-Member</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>

Register at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=A0934E0D-086E-E611-998D-0050569C00A7

Space is limited to 8 registrants.

Cancellations/refunds
Is this event refundable? Yes
If yes, requests must be submitted in writing to events@hbanet.org by February 22, 2017; no refunds are available after this date.

Event description
Interested in getting to know other HBA members? Would you like to make new friends? Want to feel inspired and empowered?

Then come have dinner with us and join the HB8 Supper Club.

This initiative will bring together small groups of eight HBA members and potential new members for a casual dinner at a local, mid-price San Francisco bay area restaurant. In this intimate setting, you and up to seven other great women will have an opportunity to get to know each other in an informal, social environment and learn more about the HBA and share your experiences.

Pre-dinner beverages will be from 6:00 to 6:30 PM to give you an opportunity to network with all your fellow diners. Dinner will then start at 6:30 PM. Out of respect for your fellow diners, please do your best to arrive on time. Also, do remember to bring business cards to take full advantage of the networking opportunities.

We’ll take care of the restaurant reservation and logistics while you bring your curiosity and enthusiasm. One HBA board or programs committee member will be attending each event. You don't know exactly who you will meet, but it's guaranteed that you will meet some amazing women.

Your host for this event will be Marge Josephson, vice president of human resources and operational services, Bay City Capital. Marge has been with the firm since the founding of
the company in 1997 by Dr. Fred Craves. She is responsible for a variety of roles including human resources, contract management, purchasing, facilities and MIS coordination. Marge sits on HBA San Francisco's board and global board. She is a member of the finance committee of the Advanced Integrative Therapy Institute.

Note: This event costs $10 for members and $15 for nonmembers to cover administrative and chapter fees (charged at registration). This fee is non-refundable. Cancellations are appreciated at least 24 hours in advance. This would allow time to notify the next person on the waitlist. You are responsible for the cost of food and beverages. If possible, please bring cash (including small bills) to make splitting the check easier.

Special instructions: Free parking is available.

Event questions/support
- Chapter contact for event: Lisa Mazzoni at lmazzoni@gene.com or 650-452-3579
- Membership questions: membership@hbanet.org or 973-575-0606 ext 1
- Online registration assistance: events@hbanet.org or 973-575-0606 ext 3

Visit us online

Registration information
The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.

The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

<table>
<thead>
<tr>
<th>Regular registration</th>
<th>Member</th>
<th>$10.00</th>
<th>$15.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular registration</td>
<td>Non-Member</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>

HBS Saturday Morning, Feb. 25, 2017

Event: “Meaningful Work: Finding Significance In Your Career with Cindy Miller PhD”
Featured speaker: Cindy Miller, Coach and organization development consultant, Cindy Miller Associates
Date and Time: Saturday, 25 February, 8:00AM - 2:00PM PST
Agenda
8:00 - 9:00 AM Networking breakfast
9:00 - 12:00 PM Workshop
12:00 - 1:00 PM Lunch break and networking
1:00 - 2:00 PM Workshop conclusion
Location: Genentech (Building 82)
651 Gateway Blvd., 15th Floor, South San Francisco, CA 94080, 650-225-1000
Registration Name Price Level Early Bird Regular
1 - Regular registration Member $45.00 $55.00
1 - Regular registration Non-Member $65.00 $75.00
2 - Genentech employee registration Member $30.00 $40.00
2 - Genentech employee registration Non-Member $30.00
Learning objectives
1. Learn how to provide more meaningful work for yourself and for people of all generations in the workplace.
2. Network with fellow HBA members and nonmembers.

Event contact
Lisa Mazzoni
650-452-3579

Event sponsors

How have you experienced meaning in your work? How can you continue to find more meaning as you advance your career?

Event Description
Join HBA San Francisco for an interactive workshop to reflect on your career and explore ways to experience more meaning in your current and future work. During the workshop, you will create your own meaningful work life graph and uncover personal sources of meaning in work. Explore the elements that contribute to the experience of significance in our work lives. Learn how to provide more meaningful work for yourself and for people of all generations in the workplace.

Speaker Bio
Cindy Miller PhD, coach and organization development consultant, will facilitate this opportunity for self-reflection and discovery. She draws on her expertise in human development, first-hand experience leading organizations in global biotech, pharma and financial services companies and her passion for encouraging others to find deeper meaning in life through their work.

Your program event fee includes a full breakfast, lunch, networking and workshop materials.

Special instructions: Please bring a valid government-issued ID card and Genentech employees please bring employee badge. Although last-minute walk in registration is welcome, attendees who are able to register on or before 23 February will have expedited security processing.

Registration information
Event is open to: HBA members and nonmembers
Online registration deadline: 23 February, 2017
Onsite (walk-in) registration: Is allowed

Cancellations/refunds
Is this event refundable? Yes
If yes, requests must be submitted in writing to events@hbanet.org by 23 February, 2017; no refunds are available after this date.

Registration information
The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the
registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.
The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

HBA Webinar, Tuesday, Feb. 28, 2017

Webinar - Creating a Feedback-Rich Culture
Featured speakers
Juliana Wood
Assoc. director online learning resources
Healthcare Businesswomen's Association
Deborah Riegel
Principal and director of learning
The Boda Group
Priya Nalkur-Pai
Leadership coach
The Boda Group
Date and Time: Tuesday, February 28, 1:00 – 2:00 pm EST, 10:00 – 11:00 am PT
Agenda
12:00 - 12:05 PM    Welcome and introductions
12:05 - 12:50 PM    Presentation
12:50 - 1:00 PM    Q&A session; thank you and closing greetings
Pricing

Registration Name  Price Level  Regular
1 - Individual registration Member  $25.00
1 - Individual registration Non-Member $35.00
2 - Group of 15 registrations Member $300.00
2 - Group of 15 registrations Non-Member $300.00
3 - Group of 25 registrations Member $500.00
3 - Group of 25 registrations Non-Member $500.00
4 - Group of 50 registrations Member $875.00
4 - Group of 50 registrations Non-Member $875.00
5 - Group of 100 registrations Member $1500.00
5 - Group of 100 registrations Non-Member $1500.00

Register at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=18379AF5-B3C7-E611-A5C2-0050569C00A7

Please note this webinar will take place from 12:00 – 1:00 PM ET. Please convert into your local time zone and mark your calendar accordingly.

Event contact
Juliana Wood
973-575-0606 ext. 1

Competencies
2. Communicates effectively
8. Builds relationships and teams

Webinar Description
Feedback helps leaders and team members align personal behaviors with organizational goals, reinforce norms and develop themselves and others in ways that create positive business outcomes. Studies show that professionals who work in organizations with a strong culture of feedback experience more engagement, greater job satisfaction, increased resiliency and even reduced pain and inflammation. When leaders create a feedback-rich culture where they offer helpful feedback in a timely manner — and are open to receiving it themselves — everyone benefits.

In this participatory workshop, you’ll learn to convey information in a way that can be heard, digested and applied moving forward, creating a positive environment that fosters learning and receptivity to feedback. You’ll discover how to apply feedback techniques to increase positive behaviors and performance, how to adapt your feedback style to different communication styles and when to give feedback (and when not to). Specific techniques for dealing with feedback-resistant employees will also be provided.

Gain confidence in this key leadership skill by practicing giving and receiving feedback with other participants. Leave this session ready to build stronger workplace relationships.

Registration information
Event is open to: HBA members and nonmembers
Online registration available until one hour before the live broadcast begins.

This webinar is nonrefundable.

Learning objectives
1. Use a proven four-step model for giving effective feedback
2. Adapt feedback style to different communication styles
3. Apply seven specific techniques for dealing with feedback-resistant employees

*************************************************
PBSS Symposium, Monday, April 24, 2017
Topic: “Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists”
Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)
Date and Time: April 24, 2017, 8:45-17:00
Location: Crowne Plaza, Foster City, CA
Registration fee (USD): Minisymposium fee: $195;
Registration: http://www.PBSS.org
Registration deadline:4/20/2017 (it will close sooner if the seating cap is reached)

Topic Description
Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.
Tentative topics and speakers:

**Morning: 8:45-12:00**
- Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech
- Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS
- Sponsor presentation
- Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck
- Prediction of circulating drug metabolites - Ming Hu, University of Houston

**Afternoon: 1:15-5:00**
- Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech
- Sponsor presentation
- Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech
- Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid of target hepatotoxicity - Raju Subramanian, Gilead
- Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech
- Carboxylic acid bioactivation via glucuronides/acyl CoA’s and application in drug discovery – Mark Grillo, Amgen